| 
			
			 The benefit of surgery was most pronounced in men who were under age 
			65 when their tumor was diagnosed, a new, long-term Scandinavian 
			study found. 
 The results, published in The New England Journal of Medicine, don't 
			apply to prostate cancer detected during screening, such as with 
			blood tests to measure prostate specific antigen (PSA).
 
 The study does, however, add new information to help guide treatment 
			of men with symptomatic or "incidentally" discovered prostate 
			cancer.
 
 But the findings are complicated by the fact that treatment options 
			have changed since the study began in the 1990s.
 
 Today, PSA testing often spots prostate tumors much earlier, and 
			patients have the option of so-called active surveillance, or 
			watchful waiting, wherein doctors closely monitor tumors and begin 
			treatment when the cancer seems to be getting aggressive. Typically, 
			prostate tumors grow so slowly that men will likely die from 
			something else before the cancer claims them.
 
			
			 
			
 Nonetheless, the results are "important because this is the longest 
			follow-up we have," said Dr. David Penson, chairman of urology at 
			Vanderbilt University Medical Center in Nashville, who wasn't 
			involved in the study. "It shows that if I have a long life 
			expectancy and if I have higher-grade disease, I probably need to 
			get some treatment because there's an advantage to surgery, and it's 
			not an insignificant advantage."
 
 "If I'm an older, sicker guy with heart disease and my life 
			expectancy is less, maybe I don't have to have it treated," Penson 
			told Reuters Health in a telephone interview. "If I have low-grade 
			disease, maybe I don't need to be treated at all regardless of how 
			old I am."
 
 "What we show is that radical prostatectomy can cure prostate cancer 
			but it's only for those who develop a lethal disease and who are 
			healthy enough to not die from something else," study leader Dr. 
			Anna Bill-Axelson of Uppsala University in Sweden told Reuters 
			Health by phone.
 
			
            [to top of second column] | 
 
			Most people have low-risk disease, she said.
 "Even in our study with advanced tumors, almost 70 percent of the 
			men died from other causes, so it shows you shouldn't treat 
			immediately, especially low- or intermediate-risk tumors," she said. 
			"You should wait and see if they get more aggressive and then treat 
			them."
 
 
			The trial involved 695 men at 14 centers in Sweden, Finland and 
			Iceland.
 During follow-up for an average of 23 years, there were 45 percent 
			fewer prostate cancer-related deaths in men who got radical surgery.
 
 By 2017, 80 percent had died from any cause. Among men who had 
			immediate surgery, 72 percent died; among those who didn't, 84 
			percent died.
 
 Prostate cancer accounted for 20 percent of deaths in the surgery 
			group and 31 percent of deaths in the watchful waiting cohort.
 
 All volunteers were under age 75 at the start, with a life 
			expectancy of at least 10 years.
 
 The cancer spread in 27 percent of the surgery group and in 43 
			percent of the watchful waiting group.
 
 Radical prostatectomy produced the most benefit among men diagnosed 
			before age 65. Among these men, "overall mortality was 15 percentage 
			points lower, mortality due to prostate cancer was 15.1 percentage 
			points lower, and the risk of metastasis was 18.6 percentage points 
			lower in the radical-prostatectomy group than in the 
			watchful-waiting group," the researchers conclude.
 
 SOURCE: https://bit.ly/2UrK62J The New England Journal of Medicine, 
			online December 12, 2018.
 
			[© 2018 Thomson Reuters. All rights 
				reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. |